Comparison of tocilizumab and tumour necrosis factor inhibitors in rheumatoid arthritis: a retrospective analysis of 1603 patients managed in routine clinical practice

Tocilizumab (TCZ) and tumour necrosis factor inhibitors (TNFi) are recommended for the treatment of rheumatoid arthritis (RA) in patients with inadequate response (IR) to prior disease-modifying antirheumatic drugs (DMARDs). This retrospective analysis assessed the efficacy of TCZ and TNFi, alone or...

Descripción completa

Detalles Bibliográficos
Autores principales: Backhaus, Marina, Kaufmann, Jörg, Richter, Constanze, Wassenberg, Siegfried, Roske, Anne-Eve, Hellmann, Peter, Gaubitz, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2015
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365186/
https://www.ncbi.nlm.nih.gov/pubmed/25630309
http://dx.doi.org/10.1007/s10067-015-2879-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4365186/
https://www.ncbi.nlm.nih.gov/pubmed/25630309
http://dx.doi.org/10.1007/s10067-015-2879-0

Ejemplares similares